Lebrikizumab  (Synonyms: TNX-650)

Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases^[1][2][3].

Lebrikizumab (500 μg/mL or 1 mg/mL, 24 h) effectively inhibits the IL-13-elicited neuronal sensitization responses to each of the 3 pruritogens in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

953400-68-5

Liquid

Colorless to light yellow

[Lebrikizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Loaded Lebrikizumab on AHC2 biosensor, can bind IL-13 Protein, Human (HEK293, His, HY-P70568) with an affinity constant of 7.283E-10 M as determined in BLI assay.

• [1]. Jonathan Corren, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98.  [Content Brief]

  [2]. Loh TY, et al. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis. J Asthma Allergy. 2020 Feb 11;13:109-114.  [Content Brief]

  [3]. Miron Y, et al. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022 Sep;150(3):690-700.  [Content Brief]